Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G. Loupakis F, et al. Br J Cancer. 2011 Apr 12;104(8):1262-9. doi: 10.1038/bjc.2011.85. Epub 2011 Mar 15. Br J Cancer. 2011. PMID: 21407216 Free PMC article. Clinical Trial.
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A. Masi G, et al. Among authors: loupakis f. Ann Oncol. 2006 Aug;17(8):1249-54. doi: 10.1093/annonc/mdl119. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766580 Free article. Clinical Trial.
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M. Ruzzo A, et al. Among authors: loupakis f. Pharmacogenomics J. 2008 Aug;8(4):278-88. doi: 10.1038/sj.tpj.6500463. Epub 2007 Jun 5. Pharmacogenomics J. 2008. PMID: 17549067
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.
Graziano F, Ruzzo A, Loupakis F, Santini D, Catalano V, Canestrari E, Maltese P, Bisonni R, Fornaro L, Baldi G, Masi G, Falcone A, Tonini G, Giordani P, Alessandroni P, Giustini L, Vincenzi B, Magnani M. Graziano F, et al. Among authors: loupakis f. Br J Cancer. 2008 Sep 2;99(5):716-21. doi: 10.1038/sj.bjc.6604555. Epub 2008 Aug 12. Br J Cancer. 2008. PMID: 18728661 Free PMC article.
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Fornaro L, Masi G, Bursi S, Loupakis F, Vasile E, Antonuzzo A, Chiara S, Pfanner E, Di Paolo A, Bocci G, Del Tacca M, Falcone A. Fornaro L, et al. Among authors: loupakis f. Cancer Chemother Pharmacol. 2009 Apr;63(5):965-9. doi: 10.1007/s00280-008-0840-5. Epub 2008 Oct 7. Cancer Chemother Pharmacol. 2009. PMID: 18839174
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.
Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B, Galluccio N, Bisonni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandroni P, Magnani M. Graziano F, et al. Among authors: loupakis f. Pharmacogenomics J. 2009 Feb;9(1):78-84. doi: 10.1038/tpj.2008.16. Epub 2008 Dec 23. Pharmacogenomics J. 2009. PMID: 19104506
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L, Silva RR, Falcone A, D'Emidio S, Fedeli SL. Catalano V, et al. Among authors: loupakis f. Br J Cancer. 2009 Mar 24;100(6):881-7. doi: 10.1038/sj.bjc.6604955. Epub 2009 Mar 3. Br J Cancer. 2009. PMID: 19259089 Free PMC article.
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A. Vasile E, et al. Among authors: loupakis f. Br J Cancer. 2009 Jun 2;100(11):1720-4. doi: 10.1038/sj.bjc.6605075. Epub 2009 May 12. Br J Cancer. 2009. PMID: 19436300 Free PMC article. Clinical Trial.
Do we need biopsies of metastases for colorectal cancer patients?
Floriani I, Santini D, Torri V, Cremolini C, Falcone A, Loupakis F. Floriani I, et al. Among authors: loupakis f. Br J Cancer. 2009 Jul 21;101(2):374-5; author reply 376. doi: 10.1038/sj.bjc.6605131. Epub 2009 Jul 7. Br J Cancer. 2009. PMID: 19584870 Free PMC article. No abstract available.
265 results